Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.

doi:10.1177/10507256251367352

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.

Thyroid : official journal of the American Thyroid Association - 1 Oct 2025

Elisei Rossella, Wirth Lori J, Capdevila Jaume, Hoff Ana Oliveira, Tahara Makoto, Sherman Eric J, Hu Mimi I, Ge Ming-Hua, Wadsley Jonathan, Vaisman Fernanda, Kopeckova Katerina, Krajewska Jolanta, Olvera Dinorath, Churchill Collin, Maeda Patricia, Gilligan Adrienne M, Lin Yan, Payakachat Nalin, Robinson Bruce, Hadoux Julien, Brose Marcia S

Abstract excerpt

Background: Progression-free survival (PFS) may not fully capture the impact of treatment on patients, especially in cancers with longer natural histories and thus, could be complemented by robust measures of patient-reported tolerability (PRT). We report the use of a novel, quantifiable PRT metric as a multiplicity-controlled endpoint to support regulatory and clinical decision-making for selpercatinib use....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Patient Reported Outcome Measures

Share to Piperidines

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Quality of Life

Source

Open in PubMed

Identifiers

PMID: 40828665
DOI: 10.1177/10507256251367352

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.PMID 40828665Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Long-term safety of selpercatinib for Rearranged during transfection ( RET) -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over timeSemantic proximity Read ↗

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.Semantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Assessing Side-Effect Bother, Burden, and Tolerability: A Qualitative Study Exploring the Content Validity of the Functional Assessment of Cancer Therapy – Item GP5Semantic proximity Read ↗

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.Semantic proximity Read ↗

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.